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ABSTRACT 
Background: Individual randomized controlled trials (RCTs) of periprocedural anticoagulation 
with bivalirudin versus heparin during percutaneous coronary intervention (PCI) have reported 
conflicting results. Study-level meta-analyses lack granularity to adjust for confounders, explore 
heterogeneity, or identify subgroups that may particularly benefit or be harmed. 
Objectives: To overcome these limitations, we sought to develop an individual patient-data 
pooled database of RCTs comparing bivalirudin versus heparin. 
Methods: We conducted a systematic review to identify RCTs in which  1000 patients with 
acute myocardial infarction (AMI) undergoing PCI were randomized to bivalirudin versus 
heparin. 
Results: From 738 identified studies, 8 RCTs met the pre-specified criteria. The principal 
investigators of each study agreed to provide patient-level data. The data were pooled and 
checked for accuracy against trial publications, with discrepancies addressed by consulting with 
the trialists. Consensus-based definitions were created to resolve differing antithrombotic, 
procedural, and outcome definitions. The project required 3.5 years to complete, and the final 
database includes 27,409 patients (13,346 randomized to bivalirudin and 14,063 randomized to 
heparin). 
Conclusions: We have created a large individual-patient database of bivalirudin versus heparin 
RCTs in patients with AMI undergoing PCI. This endeavor may help identify the optimal 
periprocedural anticoagulation regimen for patient groups with different relative risks of adverse 
ischemic versus bleeding events, including those with ST-segment and non–ST-segment 
elevation MI, radial versus femoral access, use of a prolonged bivalirudin infusion or 
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glycoprotein inhibitors, and others. Adherence to standardized techniques and rigorous validation 
processes should increase confidence in the accuracy and robustness of the results.  





Optimal periprocedural anticoagulation is fundamental for patients undergoing 
percutaneous coronary intervention (PCI).1 Heparin derivatives (predominantly unfractionated 
heparin) are the dominant agents used for periprocedural anticoagulation and have been 
successfully used for decades; however, use of heparin is hampered by its indirect mechanism of 
action (activation of anti-thrombin), unpredictable pharmacodynamics, non-specific protein 
binding, and paradoxical platelet activation, which can result in either under- or over-
anticoagulation with ischemic or hemorrhagic complications or heparin-induced 
thrombocytopenia.2 
Bivalirudin, an intravenous direct thrombin inhibitor with intrinsic antiplatelet activity, 
has been under investigation for use in PCI for the past 2 decades. Initial trials suggested a lower 
risk of bleeding with bivalirudin-based compared with heparin-based regimens, and some studies 
even suggested reduced rates of cardiovascular and all-cause mortality.3,4 These studies led to 
widespread adoption of bivalirudin, which was—for a while—the most frequently used 
periprocedural anticoagulant for PCI in the United States5; however, an increased rate of acute 
(<24 hour) stent thrombosis with bivalirudin (likely due to its short-half-life when abruptly 
discontinued after the procedure )was observed and raised concerns.3,6,7 Attempts at overcoming 
this risk with more potent antiplatelet agents offset its bleeding advantage.8 Some trials have 
suggested that acute stent thrombosis may be reduced with a prolonged post-PCI bivalirudin 
infusion, although there is uncertainty as to the optimal infusion dose and duration.9-11 The 
differential use of planned or bailout use of glycoprotein IIb/IIIa inhibitors (GPIs) in the 
randomized arms in many trials has made a comparison between heparin and bivalirudin 
difficult. In addition, whether these risks and benefits are specific to patients with ST-segment 
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elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI), or to those undergoing 
PCI with radial versus femoral vascular access is unclear. 
To explore these issues, several study-level meta-analyses have been performed, 
reporting variable results.4,12-14 Such studies, while relatively easy to conduct using widely 
available statistical software packages, cannot provide in-depth assessment in subgroups, 
adequately account for heterogeneity of findings across the studies, adjust for confounders, or 
directly explore time-related effects (Table 1). In contrast, pooling individual patient-level data 
(IPD) provides the capability for more accurate assessment of the exposure and outcome 
variables (including multivariable adjustment for confounders), examination of the temporal 
relationships of therapies, and identification of specific patient subgroups in whom a more 
favorable risk-benefit profile may be identified.4,15,16 Such efforts, however, are substantially 
more complex, time consuming, and resource intensive. 
We herein describe the methodology and process of the development of a large pooled 
database of IPD from RCTs of patients with acute myocardial infarction (AMI) undergoing PCI 
who were allocated to receive a bivalirudin-based regimen versus a heparin-based regimen. 
 
METHODS 
Search strategy. This study was performed according to the Preferred Reporting Items 
for Systematic Review and Meta-Analyses of Individual Participant Data (PRISMA-IPD) 
statement17 and has been registered at the International prospective register of systematic reviews 
(PROSPERO; https://www.crd.york.ac.uk/prospero/; CRD42019132715). We searched 
MEDLINE with PubMed interface to identify RCTs that compared the use of bivalirudin-based 
versus heparin-based regimens in patients with AMI who underwent PCI (broad search query: 
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("bivalirudin" [Supplementary Concept] OR bivalirudin*[TI] OR hirulog*[TI]) AND (random* 
OR control* OR trial*)). We also reviewed the existing study-level meta-analyses and reviewed 
their reference lists to source any additional potential RCTs (date of last search: August 17, 
2018). 
 Study inclusion and exclusion criteria. We assessed the relevance of the studies based 
on the patients, intervention, control, and outcomes (PICO) principles. To be considered for 
inclusion, the trials were required to be an RCT of patients with AMI undergoing PCI allocated 
to bivalirudin-based versus a heparin-based anticoagulant regimen. Prior studies have shown that 
the accuracy of estimates provided in small randomized trials is uncertain18 and may have biased 
estimates of treatment effect. Further, merging numerous small trials at the patient level will 
create practical challenges for identifying common definitions for the pooled data. We therefore 
included only RCTs that enrolled at least 1,000 patients with AMI (either NSTEMI or STEMI). 
 Patient inclusion and exclusion criteria. Among the identified RCTs, we only included 
patients with AMI meeting at least one of the following criteria: (i) coded by the original trialists 
as STEMI; (ii) coded by the original trialists as unstable angina or NSTEMI with at least one set 
of positive pre-procedural cardiac biomarkers in the database; or (iii) coded by the original 
trialists as NSTEMI along with explicit trial-level protocol processes requiring positive cardiac 
biomarkers for NSTEMI designation. We excluded patients with stable angina as well as those 
with biomarker-negative unstable angina (i.e., in the absence of NSTEMI or STEMI). 
We included patients randomized to heparin (unfractionated or low molecular weight) 
with either planned or unplanned (bailout) use of glycoprotein IIb/IIIa inhibitors and patients 
randomized to bivalirudin with unplanned GPI use. We excluded patients randomized to 
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bivalirudin plus planned use of GPI since this regimen was never recommended for use in 
practice nor widely studied. Further, we excluded the patients who did not have a PCI attempt.  
 Data elements. We collected patient data on demographics, baseline medical history 
(including diabetes, smoking status, hypertension, dyslipidemia, others), vital signs, laboratory 
tests (hemoglobin, platelet count, and serum creatinine), procedural information (access site, 
clinical presentation [NSTEMI, STEMI]), PCI characteristics (including the vessel treated, stent 
type, and baseline and final Thrombolysis in Myocardial Infarction [TIMI] flow), peri-
procedural medications (specifically detailed timing and dosage data for bivalirudin and heparin 
[pre-, during, and post-PCI]), aspirin, P2Y12 inhibitors, and GPIs), discharge medications, and 
clinical outcomes (see below). The most essential data elements were pre-specified for inclusion 
(e.g., clinical presentation, access site, medication regimens, etc.), but all data that were common 
to the majority of the included studies were collected. 
 Outcome measures. The main outcome measures are all-cause death, cardiac death, MI, 
stent thrombosis, ischemia-driven or clinically-driven target-vessel revascularization, stroke, and  
major adverse cardiovascular and cerebrovascular events (MACCE) events. We defined 
MACCE as the 30-day composite of all-cause death, MI, stroke, or ischemia/clinically-driven 
target vessel revascularization. 
The definitions of death, cardiac death, MI, stent thrombosis, stroke, and repeat 
revascularization were sufficiently similar across studies to be pooled. Small differences in the 
definitions of these endpoints between studies are footnoted. Stent thrombosis was defined 
according to the Academic Research Consortium (ARC) definite or probable criteria, and further 
categorized as acute (<24 hours post-PCI), subacute (between day 1 and day 30 post-PCI), and 
late (after day 30).19 With respect to bleeding outcomes, no single bleeding classification was 
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common to all studies. The TIMI and Bleeding Academic Research Consortium (BARC)20 
classifications were most commonly used. Both TIMI major or minor and BARC major bleeding 
events have been strongly associated with subsequent mortality with similar prognostic 
correlation,21 and one or both types were reported in all studies (with TIMI bleeding more 
commonly available). In the pooled analysis, we therefore a priori defined “serious bleeding” as 
the presence of either TIMI major or minor bleeding (if available), or, alternatively, BARC type 
3 or 5 bleeding. 
The longest follow-up data available were requested for all outcome measures. Whether 
outcomes were adjudicated by an independent clinical events committee (CEC) or investigator-
reported were noted. CEC-adjudicated data took preference whenever available. 
Primary and secondary endpoints. Prior to any analyses the primary efficacy endpoint 
in the pooled cohort has been pre-specified as the 30-day rate of all-cause mortality, and the 
primary safety endpoint is the 30-day rate of serious bleeding (as defined above). Secondary 
endpoints include the rates of cardiac death, MI, stent thrombosis, stroke, repeat 
revascularization, MACCE, bleeding, thrombocytopenia, and net adverse clinical events (NACE; 
a composite of MACCE or serious bleeding) at 30 days and 1 year. 
 Process of data acquisition. The principal investigator of the pooling effort (G.W.S.) 
contacted the principal investigator of each trial that fulfilled the inclusion/exclusion criteria to 
solicit their participation. The data received from the studies that met the criteria were stored and 
validated at the Data Coordinating Center (DCC) of the Cardiovascular Research Foundation 
(CRF; New York, NY, United States).  
 Data audit and cleaning. A centralized database was established and validated as 
follows: Biostatisticians and clinicians from the CRF DCC created table shells based on the case 
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report forms from each included trial. Raw data from each of the included trials was then 
transformed into clean patient-level analysis datasets using standardized variable names and data 
attributes. Tables were then constructed using the actual pooled analysis database. These tables 
summarizing the individual RCT data were first audited and revised by the DCC for erroneous 
entries and programming errors. After correction, the tables were delivered to a team of 5 
clinician investigators (B.B., S.C., G.M., B.R., G.W.S.), who reviewed the data for clinical 
meaningfulness, cross-checked the tables with each trial’s primary publications, requested 
additional clinically-relevant data elements from the principal investigator of each trial, and 
performed additional edit checks. Regular group meetings with participation from the 
programming and biostatistics team (T.M., A.C., Y.L., Z.Z., M.L., Y.Z.), publications office 
(D.P.F.), and the clinical investigators (B.B., S.C., G.M., B.R.) under the supervision of G.W.S. 
took place. Additional contacts were required between the DCC and the principal investigator of 
each of the included trials numerous times for additional data or for methodological or data 
clarifications. The above cleaning algorithm was iterated until the raw data included all required 
elements and the outcomes conformed to the individual primary publications of the included 
trials. In some cases, small discrepancies were present for explainable reasons (e.g. database 
updated after the primary report). A publications committee (consisting of the principal 
investigators from each trial) will consider requests for analyses from outside investigators, 
which, if approved, will be run at CRF. 
 Statistical methodology. Continuous variables will be presented as mean and standard 
deviation (or median with 25th and 75th percentiles) and compared by trial-adjusted analysis of 
variance (ANOVA) models (or Kruskal-Wallis test for non-normally distributed data). 
Categorical variables will be reported as percentages and frequencies and compared using a trial-
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stratified Cochran-Mantel-Haenszel test. Time-to-event variables will be presented as cumulative 
event rates estimated by Kaplan-Meier methodology and number of events and compared using a 
trial-stratified log-rank test. 
 The primary study objective is to determine the optimal anticoagulant to be used during 
PCI in patients with AMI. For logistical or study design-related reasons, several of the trials 
randomized patients in the emergency room, and not all patients were biomarker positive or 
underwent PCI. However, in the current era, the decision to use heparin vs. bivalirudin for PCI in 
AMI is usually made in the catheterization laboratory, just before the intervention, and once this 
decision is made, a PCI attempt always follows. As such, the primary study cohort will be a 
modified intention-to-treat population consisting of all AMI patients in whom PCI was 
attempted. AMI patients in whom PCI was not attempted will thus be excluded from the primary 
analysis. Post-randomization exclusions may introduce differences between groups. To address 
these issues, we will do the following: (1) The principal analyses will be covariate-adjusted, 
using a pre-specified set of baseline variables; (2) We will also compare the patients in the main 
analysis cohort (N=27,407) versus those excluded post-randomization (N=6,510); (3) As a 
sensitivity analysis, we will report the main analyses in the original ITT populations, recognizing 
that the inclusion of patients not undergoing PCI will bias the analysis to the null.   
Primary analysis will be performed using a Cox regression model (one-stage approach) 
adjusting for study as a random-effect (frailty term). The frailty term will be assumed to follow a 
lognormal distribution. Data will be summarized by hazard ratios (HR) with 95% CI. These 
models have been shown to be robust in cases where the comparison groups are imbalanced 
between trials.22 The pre-specified variables for adjustment in the primary analysis include: age, 
sex, weight, recent smoking, history of diabetes, hypertension, hyperlipidemia, prior myocardial 
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infarction, radial vs femoral access, presentation with NSTEMI vs STEMI, baseline hemoglobin, 
baseline calculated creatinine clearance, US vs. EU vs. other enrolling sites, use of pre-
randomization heparin, and pre-treatment with no P2Y12 inhibitor vs. clopidogrel vs. 
prasugrel/ticagrelor, all adjusted by study as a random effect. In addition, multivariable analyses 
will be performed to adjust for baseline, procedural, and adjunct medication use variables 
(including adjunct antithrombotic agents, which may have been differentially used across the 
trial arms across the trials). Further, a study-level meta-analysis (two-stage approach) will be 
examined using both a Mantel–Haenszel fixed effect model and a DerSimonian and Laird 
random effect model. Data will be summarized by relative risks (RR) with 95% CI. 
Heterogeneity between trials will be evaluated with Cochran’s Q test and the I2 statistic (with 
<25%, 25% - 50%, and >50% indicating low, moderate, and high heterogeneity, respectively). 
Differences in outcomes across trials and the validity of the Cox proportional hazards 
model will be tested. Study heterogeneity will be assessed by the Breslow-Day test. The 
proportionality assumption will be assessed visually with plots of the Schoenfeld residuals versus 
the log of time for each predictor and formal testing will be performed using the method of 
Grambsch and Therneau.23 If the proportional hazards assumption is violated, logistic regression 
models will be used including trial as a random effect. 
Outcomes will also be analyzed across subgroups according to demographic, clinical, and 
procedural variables that predict high ischemic and bleeding risk. Specifically, the subgroups of 
greatest interest are: (i) Presentation with STEMI versus NSTEMI); (ii) use of radial versus 
femoral vascular access; (iii) the use, dose, and duration of a bivalirudin post-PCI infusion; (iv) 
the planned versus unplanned use of glycoprotein IIb/IIIa inhibitors in heparin-treated patients; 
(v) the dose and timing of heparin administration; (vi) the adjunctive use of clopidogrel versus 
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the more potent P2Y12 receptor inhibitors ticagrelor or prasugrel; (vii) use of oral anticoagulants 
at discharge; (viii) men versus women; (ix) older adults (aged >65 years) versus others, and other 
demographic, clinical, and procedural variables including but not limited to age, sex, diabetes, 
anemia, renal function, and stent type (drug-eluting versus bare metal). We will perform 
multiplicative interaction testing to examine whether treatment-related differences in relative risk 
exist across the clinical subgroups. A p value of 0.05 will be used for the threshold of 
significance for these tests. 
Sensitivity analysis for missing data will be performed using multiple imputation 
methods.24 All statistical tests will be 2-sided, and a p value of <0.05 will be considered 
statistically significant unless otherwise specified. Finally, in addition to the principal analyses of 
bivalirudin versus heparin safety and effectiveness, the database may support additional analyses 
not necessarily related to procedural anticoagulation. 
Funding. The project was partially supported by a research grant from The Medicines 
Company (Parsippany, NJ, United States) to CRF. The sponsor had no role in the design of the 
study, the review or analysis of the data, or publication rights. Additional funding support for 
programmer and biostatistician time and database maintenance was provided from CRF. 
 
STUDY SCREENING AND DATABASE CHARACTERISTICS 
Study-level screening and inclusion. From 738 identified publications via the PubMed 
search, 29 were further considered for inclusion (Table 2).3,6-8,10,25-48 Finally, 8 trials met 
eligibility criteria for the pooled analysis systematic review (Figure 1).3,6,7,10,25-28 G.W.S. was the 
principal investigator of 2 eligible studies that were available for IPD analysis.3,25 The principal 
investigators of the other 6 trials6,7,10,26-28 were contacted for participation. Each investigator 
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agreed and transferred de-identified IPD to the CRF DCC (Figure 2 and Table 3). The study 
protocol of each original trial had been approved by appropriate ethics committees at each 
participating center, and all enrolled patients had provided informed consent. 
Patient-level screening and inclusion. The 8 included randomized a total of 38,565 
patients. A total of 11,156 patients were excluded from the pooled database, including 4,646 
patients who were randomized to bivalirudin plus planned use of glycoprotein inhibitors, 2,471 
with biomarker-negative unstable angina, and 4,039 patients who did not undergoing a PCI 
attempt (Figure 3). 
 Basic characteristics of the final pooled cohort. The final pooled IPD cohort included 
27,409 patients (13,346 randomized to bivalirudin and 14,063 randomized to heparin). The 
minimum and maximum follow-up duration in the pooled database ranged from 180 to 365 days. 
Consensus-based definitions for the main outcomes in the pooled database are provided in Table 
4. Most of the outcomes among the included trials were adjudicated (Table 5). Table 6 
summarizes the Cochrane risk of bias among the included trials. 
The project began in December 2015. The validated IPD-pooled database is nearly 
complete and is expected to be locked in June 2019, after which the analyses will commence. 
 
DISCUSSION 
Effective periprocedural anticoagulation for patients undergoing PCI in AMI is required 
to suppress ischemic complications from the thrombotic coronary syndrome as well as from the 
interventional procedure itself. An inherent risk of hemorrhagic complications is introduced with 
use of all such agents. The optimal anticoagulation regimen would most favorably balance these 
competing risks, a calculus which may depend on individual patient and procedural 
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characteristics. Despite numerous large-scale RCTs of bivalirudin versus a heparin during PCI in 
AMI, the optimal anticoagulation regimen remains uncertain, and there is likely no “one size fits 
all” solution. Specifically, the relative risk: benefit profile of bivalirudin versus heparin may 
depend on clinical factors such as age, sex, renal function, and the presence of anemia; 
presentation with NSTEMI versus STEMI, which are characterized by varying patient risk 
comorbidities and thrombotic potential; procedural factors such as use of femoral or radial 
access; the dose of heparin used; adjunct medication use such as pre-randomization heparin use, 
unplanned versus planned GPI, and P2Y12 receptor inhibitor potency; and the use of, dosing, 
and duration of a bivalirudin post-PCI infusion. Even though numerous study-level systematic 
reviews and meta-analyses have been published,4,12,13,49 none has clearly identified subgroups 
that may particularly benefit from a bivalirudin-based or a heparin-based regimen. Such studies 
are also unable to account for heterogeneity in endpoint measures, adjust for confounders, or 
examine the temporal relationships in outcomes. Although an IPD cannot overcome limitations 
such as treatment differences across trials over time (such as changes in stent technologies or 
other ancillary therapies), an IPD pooled analysis is the most comprehensive way to explore the 
comparative effectiveness of these treatment strategies, overcoming many of the limitations 
inherent in study-level meta-analyses.50-52 We have therefore endeavored to create a large pooled 
IPD database of trials of bivalirudin-based versus heparin-based procedural anticoagulation 
regimens in patients with AMI undergoing PCI.  
Recent reviews have emphasized the advantages of IPD pooled analyses compared with 
standard study-level data meta-analyses.15 Adherence to PRISMA-IPD standardized techniques 
for pooling the data,17 pre-specification of a statistical analysis plan and study registration 
(PROSPERO), and application of rigorous validation processes should increase confidence in the 
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accuracy and robustness of the results; however, despite the advantages of IPD pooled analyses, 
such efforts are inherently more complex, time-consuming and resource intensive. Given the 
exacting requirements and meticulousness of the processes described herein, the present project 
took 3.5 years to finalize and validate the database, admittedly much longer than anticipated. 
Serious challenges were confronted in comprehensive data collection, clarifying data dictionaries 
and resolving varying study definitions. Some desired data elements were (unfortunately) not 
collected in all the trials, and some collected data elements had not yet been cleaned, requiring a 
coordinated effort with each individual trial DCC. Substantial time was also required to reconcile 
the data provided against that reported in prior publications. Most such discrepancies were 
minor, but all required investigation and correction or reconciliation. Although a 3.5-year 
process is not desirable, we believe that a lesser effort would have permitted inconsistencies and 
errors in the database which would have eroded confidence in the initiative and reduced the 
precision and accuracy of the results. Our learned experience from the process of pooling these 
trials may be helpful to other investigators planning large-scale IPD meta-analyses, enhancing 
the efficiency and validity of such efforts (Figure 4). 
In conclusion, this systematic review and IPD pooled meta-analysis will help provide 
better evidence for the safety and efficacy of bivalirudin-based versus heparin-based procedural 
anticoagulation in patients with AMI undergoing PCI. It is our hope that these results (expected 
in late 2019 or early 2020) will impact clinical decision-making, improve patient outcomes, 
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Figure 1. Flow Diagram of Study Selection 
 
Figure 2. Graphical Abstract of the Included Trials 
GPI = glycoprotein IIb/IIIa inhibitor. 
 
Figure 3. Flow Diagram of Patient Selection from the Included Studies 
NSTEMI = non–ST-segment elevation myocardial infarction; PCI = percutaneous coronary 
intervention; STEMI = ST-segment elevation myocardial infarction. 
 
Figure 4. Process of the Design of the Pooled Analysis Database 
AMI = acute myocardial infarction; CRF = Cardiovascular Research Foundation; PI = principal 
investigator; RCT = randomized controlled trial. 
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Table 1. Advantages and Limitations of Aggregate Results Meta-analysis and Individual Patient Data Pooled Analysis 
 
Average-Effect Meta-analysis of RCTs Individual Patient Data Pooled Analysis of RCTs 
Advantages • Requires less resources 
• Requires only summary data from each trial 
• May be done quickly 
• User-friendly statistical software packages are readily 
available 
• Analyses are straight-forward and standardized 
• All studies meeting the eligibility criteria can be included 
• Greater precision in statistical estimates and increased statistical 
power 
• Analysis populations can be defined in very specific terms 
(including specific patient subgroups) 
• Variable definitions can be standardized across trials 
• Subgroup analyses and interaction testing can be performed 
• Multivariable analyses can be performed to adjust for confounders 
• Permits time-to-event analysis, competing risk analysis, recurrent 
events analysis and other complex statistical examinations 
• Consistent with recent policies for clinical trial data sharing 
 
Limitations • Statistical estimation is crude 
• Inconsistent variable definitions and heterogeneity across 
trials cannot be resolved 
• Subgroup analyses cannot be performed 
• Temporal relationships in outcomes cannot be assessed 
• Cannot adjust for measured confounders in individual trials 
and pooled analysis 
• Resource intensive 
• Requires a team of statisticians and investigators to acquire, 
compile, and validate the data 
• Can only include studies from which the principal investigators 
and sponsors are willing to share the data 
• Cannot account for unmeasured confounders or resolve all 
differences between trials 
RCT = randomized controlled trial. 
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Table 2. List of Screened Trials 





ACUITY25 Yes 2006 13,819 Patients with ACS 
MATRIX10 Yes 2015 7,213 Patients with ACS 
REPLACE 233 No 2003 6,010 Patients undergoing elective or urgent PCI (note: <1000 patients with myocardial infarction) 
VALIDATE-SWEDEHEART28 Yes 2017 6,006 Patients with STEMI or NSTEMI 
ISAR-REACT 337 No 2008 4,570 Patients with stable or unstable angina and negative biomarkers 
BAS29 No 1995 4,098 Patients with unstable or post-infarction angina (note: only 704 patients had STEMI or NSTEMI) 
HORIZONS-AMI3 Yes 2008 3,602 Patients with STEMI  
EUROMAX7 Yes 2013 2,218 Patients with STEMI 
BRIGHT27 Yes 2015 2,194 Patients with STEMI or NSTEMI 
HEAT-PPCI6 Yes 2014 1,829 Patients planned for primary PCI  
ISAR-REACT 426 Yes 2011 1,721 Patients with NSTEMI 
REPLACE 134 No 2004 1,056 Patients undergoing elective or urgent PCI (<1000 with myocardial infarction) 
PROTECT-TIMI-3036 No 2006 857 Patients with ACS (nearly half with biomarker- negative unstable angina) 
ARNO39 No 2010 850 Patients with stable or unstable coronary disease undergoing PCI 
NAPLES III47 No 2015 837 Patients undergoing elective PCI 
BRAVE 48 No 2014 548 Patients with STEMI (the trial was stopped prematurely due to slow recruitment) 
HERO30 No 1997 412 Patients with STEMI 
ARMYDA-7-BIVALVE42 No 2012 401 Patients undergoing PCI (only 47 having acute myocardial infarction) 
TENACITY41 No 2011 383 Patients undergoing PCI (the trial was terminated prematurely by the sponsor) 
NAPLES38 No 2009 335 Patients with diabetes undergoing elective PCI 
Kuchulakanti et al.35 No 2005 294 Patients with in-stent restenosis 
CACHET31 No 2002 268 Patients undergoing elective PCI 
PROBI-VIRI 240 No 2011 264 Patients undergoing primary PCI 
He et al.48 No 2016 260 Patients with STEMI (<1000) 
Xiang et al.45 No 2013 218 Patients undergoing elective PCI 
TIMI-832 No 2002 133 Patients with unstable angina or NSTEMI (the trial was terminated prematurely by the sponsor) 
Deshpande et al.43 No 2012 101 Patients undergoing elective PCI 
SWITCH III44 No 2013 100 Patients with non-ST-elevation acute coronary syndromes undergoing PCI 
Feldman et al.46 No 2014 100 Patients undergoing PCI (only 32 with acute myocardial infarction) 
ACS = acute coronary syndromes; NSTEMI = non–ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction. 
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Table 3. Basic Characteristics of the Included Studies 
Study Patient 
Population 
Randomized Treatment* Timing of 
Randomization 





4,603 patients assigned to heparin (unfractionated 60 
U/kg bolus [ACT goal of 200-250 sec] or enoxaparin) 
plus GPI, 4,604 patients assigned to bivalirudin (bolus 
of 0.1 mg/kg pre-procedurally and infusion of 
0.25mg/kg/h pre-procedurally, followed by pre-PCI 
bolus of 0.5mg/kg and an infusion rate of 1.75 
mg/kg/h during PCI) plus GPI, 4612 patients assigned 
to bivalirudin (bolus of 0.1 mg/kg pre-procedurally 
and infusion of 0.25mg/kg/h pre-procedurally, 
followed by pre-PCI bolus of 0.5mg/kg and an 
infusion rate of 1.75 mg/kg/h during PCI) alone 
during PCI 
Within 72 hours prior 
to angiography 
Ischemic endpoint (composite of 
death, MI, or unplanned 
revascularization for ischemia), 
major bleeding, and net adverse 
clinical events (composite of 
ischemia or major bleeding) 
365 days 
HORIZONS-AMI STEMI 1,802 patients randomized to unfractionated heparin 
(60 U/kg bolus, ACT goal of 200-250 sec) plus GPI, 
1,800 patients randomized to bivalirudin (bolus of 
0.75 mg/kg followed by infusion of 1.75 mg/kg/h 
during PCI) alone 
In the emergency 
room at the PCI 
hospital 
Major bleeding and net adverse 
clinical events (composite of major 
bleeding or major adverse 
cardiovascular events, including 
death, reinfarction, target-vessel 
revascularization for ischemia, or 
stroke) 
365 days 
ISAR-REACT 4 NSTEMI 861 patients randomized to unfractionated heparin (70 
U/kg, no monitoring of ACT) plus GPI, 860 patients 
randomized to bivalirudin (bolus of 0.75 mg/kg 




decision to proceed 
with PCI 
Composite of death, large recurrent 
myocardial infarction, urgent 
target-vessel revascularization, or 
major bleeding within 30 days after 
randomization 
360 days 
EUROMAX STEMI 1,116 patients randomized to unfractionated heparin 
(100 U/kg bolus), or enoxaparin, with optional GPI 
(heparin bolus dose was 60 U/kg if GPI given), 1,102 
patients randomized to bivalirudin (bolus of 0.75 
mg/kg followed by infusion of 1.75 mg/kg/h during 
PCI and 0.25 mg/kg/h [or higher if needed] for at least 
for 4 hours post-PCI) 
In the ambulance or 
the non-PCI hospital 
Composite of death or major 
bleeding not associated with 
coronary artery bypass grafting 
365 days 
BRIGHT NSTEMI or 
STEMI 
729 patients randomized to unfractionated heparin 
alone (100 U/kg bolus), 730 patients randomized to 
unfractionated heparin (60 U/kg bolus) plus GPI, 735 
patients randomized to bivalirudin alone (bolus of 
0.75 mg/kg followed by infusion of 1.75 mg/kg/h 
during PCI and continued for 30 minutes or up to 4 
hours after PCI; after which reduced-dose infusion of 
0.2 mg/kg/h was allowed for up to 20 hours) 
In the cath lab, prior 
to angiography 
Net adverse clinical events at 30 
days, a composite of all-cause 
death, reinfarction, ischemia-driven 
target vessel revascularization, 
stroke, or any BARC bleeding 
365 days 
30 
*If there were more randomizations per trial (ie, a factorial design), only the primary randomization related to the bivalirudin-based versus heparin-based regimen is summarized 
here; †only 2 trials had follow-up for >365 days (ACUITY for up to 395 days, and HORIZONS-AMI for up to 1095 days); we included follow-up of those trials only until 365 
days in the pooled database for consistency; ‡in the individual patient-data analysis, only patients with NSTEMI or STEMI meeting the inclusion and exclusion criteria described 
in the text were included. ACS = acute coronary syndromes; ACT = activated clotting time, BARC = Bleeding Academic Research Consortium; GPI = glycoprotein IIb/IIIa 
inhibitor; MI = myocardial infarction; NSTE = non–ST-elevation; NSTEMI = non–ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI 








914 patients randomized to unfractionated heparin 
(bolus of 70 U/kg, aiming for ACT >200 sec), 915 
patients randomized to bivalirudin (bolus of 0.75 
mg/kg followed by infusion of 1.75 mg/kg/h during 
PCI; re-bolus of 0.3 mg/kg if ACT <225 sec) 
In the cath lab, prior 
to completion of 
angiography 
Composite of all-cause mortality, 
cerebrovascular accident, 






3,603 patients randomized to unfractionated heparin, 
3,610 patients randomized to bivalirudin (bolus of 
0.75 mg/kg followed by infusion of 1.75 mg/kg/h 
during PCI; bivalirudin-treated patients re-
randomized to either post-PCI bivalirudin 
discontinuation continuation at PCI dose for up to 4 
hours or at a reduced dose of 0.25 mg/kg for at least 6 
hours) 







prior to PCI 
Major adverse cardiovascular 
events by 30 days (a composite of 
all-cause death, MI, or stroke), and 
net adverse clinical events (a 
composite of BARC 3 or BARC 5 







3,002 patients randomized to unfractionated heparin 
(total dose of 70-100 U/kg), 3,004 patients 
randomized to bivalirudin (bolus of 0.75 mg/kg 
followed by infusion of 1.75 mg/kg/h during PCI; 
post-procedural infusion of bivalirudin was strongly 
encouraged). Planned GPIs were not allowed. 
After angiography 
but prior to PCI 
Composite of death from any 




Table 4. Outcome Definitions for the Pooled Database 
Outcome Definition 
All-cause death Reported death due to any cause 
Cardiac death Death due to cardiac causes, such as myocardial infarction, heart failure, arrhythmia*; deaths 
of undetermined cause are also considered cardiac death 
Myocardial infarction According to the trial-specific definitions (most consistent with the Third Universal 
Definition of MI†) 
Stent thrombosis Definite or probable according to the ARC criteria. Further classified as acute (within the 
first 24 hours post-PCI), subacute (between day 1 and 30), or late (after day 30)‡. 
Revascularization Ischemia-driven (or clinically-driven) target vessel revascularization§ 
Stroke Acute ischemic or hemorrhagic stroke as defined in each trial (not including transient 
ischemic attack). 
Major adverse cardiovascular and 
cerebrovascular events (MACCE) 
A composite of all-cause death, myocardial infarction, stroke, or clinically-driven target 
vessel revascularization 
Serious bleeding TIMI minor or major bleeding (or if not available, BARC 3 or 5 bleeding)⁋ 
Net adverse clinical events (NACE) A composite of MACCE or serious bleeding 
*VALIDATE-SWEDEHEART did not include cardiac death, but included data related to cardiovascular death. †BRIGHT, EUROMAX, VALIDATE-SWEDEHEART; ‡although 
ACUITY and HORIZONS-AMI were conducted prior to the development of the ARC consensus document, the definition of stent thrombosis in those trials conforms to the ARC 
definition. For the stent thrombosis outcome, there was variation between the trials as to whether stent thrombosis related was adjudicated for treated lesions (those stented in the 
index procedure as well as before or after; available in HORIZONS-AMI, EUROMAX, HEAT-PPCI, and VALIDATE-SWEDEHEART) versus only for lesions stenting during 
the index procedure (the rest of the trials); §EUROMAX adjudicated all ischemia-driven revascularization but not target vessel versus non-target vessel revascularization 
separately; ⁋HEAT-PPCI and VAILDATE-SWEDEHEART adjudicated bleeding complications using the BARC scale. ARC = Academic Research Consortium; BARC = 
Bleeding Academic Research Consortium; TIMI = Thrombolysis in Myocardial Infarction. 
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BRIGHT Yes Yes Yes Yes (ID-TVR) Yes Yes (TIMI) 
EUROMAX Yes Yes Yes Yes (IDR) Yes 
Yes 
(TIMI)* 
HEAT-PPCI Yes Yes Yes Yes (CD-TVR) Yes 
Yes 
(BARC) 
HORIZONS-AMI Yes  Yes Yes Yes (ID-TVR) Yes  Yes (TIMI) 
ISAR-REACT 4 Yes Yes Yes Yes (ID-TVR) Yes Yes (TIMI) 
MATRIX Yes Yes Yes Yes (ID-TVR) Yes Yes (TIMI) 
VALIDATE-
SWEDEHEART 






BARC = Bleeding Academic Research Consortium; CD = clinically-driven; ID = ischemia-driven; TVR = target vessel 
revascularization. *Bleeding events in ACUITY and EUROMAX were adjudicated for 35 days. 
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ACUITY + + – – + – – 
BRIGHT + + – – + – – 
EUROMAX + + – – + – – 
HEAT-PPCI + + – – + – – 
HORIZONS-
AMI 
+ + – – + – – 
ISAR-REACT 4 + + + + + – – 
MATRIX + + – – + – – 
VALIDATE-
SWEDEHEART 
+ + – – + – – 
Key: + = low risk of bias; – = high risk of bias.  
*Unlike most of the existing average effect systematic reviews, the principal investigators of all the included trials were coauthors of the 
current systematic review and individual patient pooled analysis; therefore, there were no uncertain (yellow) cells in the risk of bias 
assessment. 
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